バイオシミュレーション市場：オファリング、デリバリーモデル、アプリケーション、エンドユーザー別-2025-2030年の世界予測

バイオシミュレーション市場は、2023年に31億米ドルと評価され、2024年には35億5,000万米ドル、CAGR14.60%で成長し、2030年には80億7,000万米ドルに達すると予測されています。

バイオシミュレーションは、ライフサイエンスの展望を再構築する重要なツールとして登場しました。この分野は、高度な計算アルゴリズムと生物学的データを融合して研究活動を合理化・強化するもので、従来の実験手順に代わる、より正確でコスト効率の高い代替手段を提供します。今日、革新的な企業は、治療結果の予測、薬物相互作用のシミュレーション、臨床試験デザインの最適化を可能にするシステムに傾注しています。高度なシミュレーションツールを活用することで、市場開拓では開発サイクルの加速、意思決定の改善、創薬・開発リスクの低減が実現しつつあります。デジタル技術の普及と効率的な調査手法に対する需要の高まりにより、バイオシミュレーションは科学的および経済的なハードルを克服するための重要な手段として脚光を浴びています。このような環境において、予測分析と複雑な生物学的モデルの融合は、前臨床試験と臨床試験の両方を進める上で不可欠なものとなっています。業界がますますデータ主導型戦略に傾倒する中、今日のバイオシミュレーション戦略は、患者ケアを変革し、世界中の業界水準を高める可能性を秘めた画期的な進歩への道を開くものです。

バイオシミュレーション市場の変革

バイオシミュレーションを取り巻く環境は、急速な技術進歩と調査手法のパラダイムシフトに後押しされ、大きな変革期を迎えています。従来の実験室実験は、スピードだけでなく分析の深度も向上させるデジタルおよび計算機による代替手法に徐々に移行しつつあります。自動化、機械学習、忠実度の高いシミュレーションモデルの統合により、研究者は複雑な生物学的現象をかつてないほど明瞭に探求できるようになりました。このような変革的シフトは、経験的データ収集への依存から予測モデリングへの移行によって特徴付けられ、より迅速な仮説検証と情報に基づく意思決定が可能になります。さらに、シミュレーションプラットフォームの進化により、製薬研究の様々な側面における独自の要件に対応する汎用性の高いツールが提供されています。その結果、業界は、反復設計と仮想テストが単なる補完的な活動ではなく、業務の青写真の中心となる、より俊敏な枠組みを採用しつつあります。規制当局の見解の変化とデジタルシミュレーションによる結果の受け入れの拡大は、この移行をさらに明確にし、バイオシミュレーションが現代の治療法の革新と研究にますます不可欠な要素となっています。

バイオシミュレーションセグメンテーションの詳細分析とその意味合い

市場は複数の方法でセグメント化されており、バイオシミュレーションの高度なレイヤーを垣間見ることができます。提供サービスに基づいて見ると、市場はサービスとソフトウェアに分けられ、サービスはさらに受託サービスと自社サービスに分けられます。一方、ソフトウェアのカテゴリーには、分子モデリングおよびシミュレーションソフトウェア、PBPKモデリングおよびシミュレーションソフトウェア、PK/PDモデリングおよびシミュレーションソフトウェア、毒性予測ソフトウェア、試験デザインソフトウェアなど、さまざまな専門ツールが含まれます。もう一つの次元は、様々な投資戦略やアクセス嗜好を反映する所有モデルと購読モデルを区別する提供モデルに基づくものです。さらに、アプリケーションベースのセグメンテーションは、医薬品開発と創薬の二重の焦点を強調します。医薬品開発そのものは、臨床試験や前臨床試験といったニュアンスに螺旋状に広がり、後者はさらにADME/ToxとPK/PDの考察に細分化されます。対照的に、創薬では、標的の同定と検証とともに、リードの同定と最適化といった技術が重視されます。最後に、エンドユーザーに基づくセグメンテーションでは、受託研究機関、製薬・バイオテクノロジー企業、規制当局、研究機関によって市場を分類し、それぞれがバイオシミュレーションバリューチェーンを推進する上で明確な役割を果たしています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療の調査への重点化
    • 安全な医薬品の開発を促進するためのバイオシミュレーションの使用に対する規制当局の承認
  • 抑制要因
    • バイオシミュレーションのインストールと技術開発にかかる価格の引き上げ
  • 機会
    • 新規生物学的療法を強化するためのシミュレーションソリューションの継続的な進歩
    • 医薬品開発と医薬品試験への投資増加
  • 課題
    • 正確な結果を生み出すための複雑さと認識の欠如
• 市場セグメンテーション分析
  • 提供内容：バイオシミュレーションにおけるモデル構築、シミュレーション、分析、視覚化のためのプラットフォームを提供するソフトウェアの使用が増加しています
  • デリバリーモデル：バイオシミュレーションでは初期コストが低いため、所有権モデルが好まれる傾向が高まっています。
  • 応用：臨床試験におけるバイオシミュレーションの適用拡大
  • エンドユーザー：製薬・バイオテクノロジー企業におけるバイオシミュレーションの採用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 バイオシミュレーション市場：提供別

• サービス
  • 契約サービス
  • 社内サービス
• ソフトウェア
  • 分子モデリングおよびシミュレーションソフトウェア
  • PBPKモデリングおよびシミュレーションソフトウェア
  • PK/PDモデリングおよびシミュレーションソフトウェア
  • 毒性予測ソフトウェア
  • 試験設計ソフトウェア

第7章 バイオシミュレーション市場配信モデル別

• 所有権モデル
• サブスクリプションモデル

第8章 バイオシミュレーション市場：用途別

• 医薬品開発
  • 臨床試験
  • 前臨床試験
    • ADME/毒性
    • PK/PD
• 創薬
  • リードの特定と最適化
  • ターゲットの特定と検証

第9章 バイオシミュレーション市場：エンドユーザー別

• 契約調査機関
• 製薬・バイオテクノロジー企業
• 規制当局
• 調査機関

第10章 南北アメリカのバイオシミュレーション市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のバイオシミュレーション市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのバイオシミュレーション市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Advanced Chemistry Development, Inc.
• Aitia
• Allucent
• Biomed Simulation, Inc.
• BioSimulation Consulting Inc.
• Cadence Design Systems, Inc.
• Cell Works Group, Inc.
• Certara, Inc.
• Chemical Computing Group ULC
• Crystal Pharmatech Co., Ltd.
• Cytel Inc.
• Dassault Systemes SE
• ICON PLC
• In Silico Biosciences, Inc.
• INOSIM Software GmbH
• Instem PLC
• Model Vitals
• Physiomics PLC
• Quotient Sciences Limited
• Resolution Medical
• Schrodinger, Inc.
• Simulations Plus, Inc.
• Thermo Fisher Scientific Inc.
• VeriSIM Life
• VIRTUALMAN
• Yokogawa Electric Corporation

LIST OF FIGURES

• FIGURE 1. BIOSIMULATION MARKET MULTI-CURRENCY
• FIGURE 2. BIOSIMULATION MARKET MULTI-LANGUAGE
• FIGURE 3. BIOSIMULATION MARKET RESEARCH PROCESS
• FIGURE 4. BIOSIMULATION MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOSIMULATION MARKET DYNAMICS
• TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 68. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 69. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 70. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 71. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 73. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 74. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 75. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 115. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 116. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 117. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 118. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 120. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 121. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 122. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 124. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 125. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 126. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 127. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 129. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 130. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 131. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 136. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 144. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 145. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 152. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 153. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 154. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 160. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 161. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 162. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 163. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 169. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 170. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 171. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 172. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 178. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 179. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 180. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 187. TAIWAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 188. TAIWAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 189. TAIWAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 190. TAIWAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. THAILAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 196. THAILAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 197. THAILAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 198. THAILAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 199. THAILAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. VIETNAM BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 205. VIETNAM BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 206. VIETNAM BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 207. VIETNAM BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 208. VIETNAM BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 223. DENMARK BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 224. DENMARK BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 225. DENMARK BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 226. DENMARK BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 227. DENMARK BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. EGYPT BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 233. EGYPT BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 234. EGYPT BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 235. EGYPT BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 236. EGYPT BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 241. FINLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 242. FINLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 243. FINLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 244. FINLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 245. FINLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 250. FRANCE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 251. FRANCE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 252. FRANCE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 253. FRANCE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 254. FRANCE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 255. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 259. GERMANY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 260. GERMANY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 261. GERMANY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 262. GERMANY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 263. GERMANY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. ISRAEL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 269. ISRAEL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 270. ISRAEL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 271. ISRAEL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 272. ISRAEL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 277. ITALY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 278. ITALY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 279. ITALY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 280. ITALY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 281. ITALY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 282. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 283. ITALY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 284. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 285. ITALY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 286. NETHERLANDS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 287. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 288. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 289. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 290. NETHERLANDS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 291. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 292. NETHERLANDS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 293. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 294. NETHERLANDS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 295. NIGERIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 296. NIGERIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 297. NIGERIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 298. NIGERIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 299. NIGERIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 300. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 301. NIGERIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 302. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 303. NIGERIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 304. NORWAY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 305. NORWAY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 306. NORWAY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 307. NORWAY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 308. NORWAY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 309. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 310. NORWAY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 311. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 312. NORWAY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 313. POLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 314. POLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 315. POLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 316. POLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 317. POLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 318. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 319. POLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 320. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 321. POLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 322. QATAR BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 323. QATAR BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 324. QATAR BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 325. QATAR BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 326. QATAR BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 327. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 328. QATAR BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 329. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 330. QATAR BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 331. RUSSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 332. RUSSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 333. RUSSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 334. RUSSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 335. RUSSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 336. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 337. RUSSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 338. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 339. RUSSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 340. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 341. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 342. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 343. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 344. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 345. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 346. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 347. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 348. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 349. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 350. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 351. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 352. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 353. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 354. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 355. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 356. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 357. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 358. SPAIN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 359. SPAIN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 360. SPAIN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 361. SPAIN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 362. SPAIN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 363. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 364. SPAIN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
• TABLE 365. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 366. SPAIN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 367. SWEDEN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 368. SWEDEN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 369. SWEDEN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
• TABLE 370. SWEDEN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
• TABLE 371. SWEDEN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (U

The Biosimulation Market was valued at USD 3.10 billion in 2023 and is projected to grow to USD 3.55 billion in 2024, with a CAGR of 14.60%, reaching USD 8.07 billion by 2030.

Biosimulation has emerged as a vital tool that is reshaping the life sciences landscape. This discipline blends advanced computational algorithms with biological data to streamline and enhance research activities, offering a more precise and cost-effective alternative to traditional experimental procedures. Today, innovative organizations are leaning into systems that can predict outcomes, simulate drug interactions, and optimize clinical trial designs. By leveraging sophisticated simulation tools, the market is witnessing accelerated development cycles, improved decision-making, and reduced risk in drug discovery and development. The proliferation of digital technologies and increased demand for efficient research methodologies have propelled biosimulation into the spotlight as a key enabler for overcoming scientific and financial hurdles. In this environment, the fusion of predictive analytics with complex biological models is proving indispensable in advancing both preclinical and clinical studies. With the industry increasingly leaning on data-driven strategies, today's biosimulation strategies pave the way for breakthroughs that hold the potential to transform patient care and elevate industry standards across the globe.

Transformative Shifts in the Biosimulation Landscape

The biosimulation landscape is undergoing profound transformations, fueled by rapid technological advancements and a paradigm shift in research methodologies. Traditional laboratory experiments are gradually making way for digital and computational alternatives that offer not only speed but also a greater depth of analysis. The integration of automation, machine learning, and high-fidelity simulation models is empowering researchers to explore complex biological phenomena with unprecedented clarity. These transformative shifts are characterized by a move from reliance on empirical data collection towards predictive modeling, enabling faster hypothesis testing and more informed decision-making. Moreover, the evolution of simulation platforms is providing versatile tools that cater to the unique requirements of various aspects of pharmaceutical research. As a result, the industry is embracing a more agile framework where iterative design and virtual testing are not just complementary activities, but central to the operational blueprint. The changes in regulatory perspectives and the growing acceptance of digitally simulated outcomes further underline this transition, making biosimulation an increasingly integral part of modern therapeutic innovation and research.

In-Depth Analysis of Biosimulation Segmentation and Its Implications

The market is segmented in multiple ways which offer a window into the sophisticated layers of biosimulation. When viewed based on the offering, the market divides into services and software, where services are further broken down into contract services and in-house services, whereas the software category encompasses a range of specialized tools including molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, toxicity prediction software, and trial design software. Another dimension is based on the delivery model, which distinguishes between ownership models and subscription models, reflecting varied investment strategies and access preferences. Moreover, application-based segmentation highlights the dual focus on drug development and drug discovery. Drug development itself spirals into nuances such as clinical trials and preclinical testing, with the latter further delineated into ADME/Tox and PK/PD considerations. In contrast, drug discovery emphasizes techniques such as lead identification and optimization alongside target identification and validation. Lastly, segmentation based on end-user categorizes the market according to contract research organizations, pharmaceutical and biotechnology companies, regulatory authorities, and research institutes, each playing their distinct role in driving the biosimulation value chain.

Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software.

Based on Delivery Model, market is studied across Ownership Models and Subscription Models.

Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation.

Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes.

Regional Dynamics Shaping the Global Biosimulation Market

Regional insights reveal a complex mosaic of opportunities and challenges that are reshaping the biosimulation arena. In the Americas, a blend of strong research institutions and robust funding mechanisms fosters an environment where biosimulation tools are rapidly adopted and refined. The region stands out with its strong regulatory frameworks and strategic partnerships that spearhead innovation. In the Europe, Middle East & Africa region, the convergence of academic research and industrial expertise creates a vibrant ecosystem. Here, well-established pharmaceutical hubs collaborate with technology providers to drive efficiency and bolster regulatory compliance, ensuring that simulation technologies align with regional standards. Meanwhile, the Asia-Pacific region is witnessing significant growth fueled by increasing investments in research and development, a surge in tech-driven startups, and expanding capabilities in digital health. This geographically diverse spread of opportunities underscores the need for tailored strategies that cater to local market dynamics, competitive pressures, and intercultural variations in research methodologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Industry Leaders Driving Biosimulation Innovation

Industry insights highlight the emergence of several key players who are instrumental in advancing the field of biosimulation. Leaders such as Advanced Chemistry Development, Inc. and Aitia are at the forefront of integrating computational modeling into everyday research routines. Companies like Allucent, Biomed Simulation, Inc., and BioSimulation Consulting Inc. bring specialized expertise that enhances the scope and precision of simulation strategies employed throughout the sector. This is complemented by the innovation drive of Cadence Design Systems, Inc., Cell Works Group, Inc., and Certara, Inc., along with Chemical Computing Group ULC and Crystal Pharmatech Co., Ltd. Additional trailblazers including Cytel Inc., Dassault Systemes SE, ICON PLC, and In Silico Biosciences, Inc. are redefining industry benchmarks. INOSIM Software GmbH, Instem PLC, Model Vitals, and Physiomics PLC, among others like Quotient Sciences Limited, Resolution Medical, and Schrodinger, Inc., further bolster the competitive landscape. The influence of companies such as Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation cannot be overstated in the ongoing drive towards more efficient, reliable, and transformative biosimulation methodologies.

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Crystal Pharmatech Co., Ltd., Cytel Inc., Dassault Systemes SE, ICON PLC, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation. Strategic Recommendations for Biosimulation Industry Leaders

For industry leaders, the evolving landscape presents multiple avenues for strategic advancement. It is imperative to invest in next-generation simulation platforms that blend advanced computational power with intuitive user interfaces, thereby enhancing both predictive accuracy and operational efficiency. Fostering partnerships with technology providers can facilitate access to innovative tools while also offering new collaborative research opportunities. Leaders should prioritize dynamic talent development programs that not only cultivate expertise in simulation technologies but also encourage cross-disciplinary synergy between data science, biology, and regulatory affairs. Embracing flexible engagement models such as subscription-based solutions may reduce upfront costs and stimulate broader adoption of emerging technologies. In addition, benchmarking against industry pioneers and integrating real-world data analytics into simulation frameworks can significantly improve overall performance. These actionable approaches offer a roadmap for capitalizing on the transformative potential of biosimulation, ensuring that organizations remain agile, competitive, and well-equipped to address rapidly evolving market requirements.

Conclusion: The Future of Biosimulation in a Rapidly Evolving Landscape

In summary, the biosimulation market is positioned at a critical juncture where technological innovation and strategic foresight converge to redefine research paradigms. The shift from conventional experimental models to data-driven simulation techniques underscores the importance of adaptability and proactive investment in advanced methodologies. A detailed segmentation analysis reveals the multifaceted nature of the market, spanning various offerings, delivery models, applications, and end-users. This complexity is further complemented by distinct regional dynamics and the presence of pioneering companies whose innovative endeavors are setting new industry benchmarks. The insights gained from examining these factors converge to offer a comprehensive understanding of the current state and future trajectory of biosimulation. Ultimately, the key to sustained success in this rapidly evolving field lies in the ability to harness technological advancements, nurture collaborative ecosystems, and maintain a steadfast commitment to continuous improvement and operational excellence.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing emphasis on research of personalized medicine
    • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
    • 5.1.3.2. Rising investments for drug developments and drug testings
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
  • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation owing to its lower initial costs
  • 5.2.3. Application: Increasing application of biosimulation for clinical trials
  • 5.2.4. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biosimulation Market, by Offering

• 6.1. Introduction
• 6.2. Services
  • 6.2.1. Contract Services
  • 6.2.2. In-House Services
• 6.3. Software
  • 6.3.1. Molecular Modeling & Simulation Software
  • 6.3.2. PBPK Modeling & Simulation Software
  • 6.3.3. PK/PD Modeling & Simulation Software
  • 6.3.4. Toxicity Prediction Software
  • 6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model

• 7.1. Introduction
• 7.2. Ownership Models
• 7.3. Subscription Models

8. Biosimulation Market, by Application

• 8.1. Introduction
• 8.2. Drug Development
  • 8.2.1. Clinical Trials
  • 8.2.2. Preclinical Testing
    • 8.2.2.1. ADME/Tox
    • 8.2.2.2. PK/PD
• 8.3. Drug Discovery
  • 8.3.1. Lead Identification & Optimization
  • 8.3.2. Target Identification & Validation

9. Biosimulation Market, by End-User

• 9.1. Introduction
• 9.2. Contract Research Organizations
• 9.3. Pharmaceutical & Biotechnology Companies
• 9.4. Regulatory Authorities
• 9.5. Research Institutes

10. Americas Biosimulation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biosimulation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. ProductLife Group enhances drug development capabilities with IntiQuan acquisition for innovative biosimulation solutions
  • 13.3.2. Cytel's new East Horizon platform enhances adaptive trial design with cloud integration
  • 13.3.3. Orion and Aitia leverage AI-driven digital twins to revolutionize drug discovery in oncology sector
  • 13.3.4. Biosimulation and tumor microenvironment modeling enhance precision of immunotherapy predictions for NSCLC patients
  • 13.3.5. Quantum breakthroughs in biosimulation revolutionize drug discovery with cutting-edge precision modeling
  • 13.3.6. Certara to acquire Chemaxon to enhance drug discovery and biosimulation capabilities
  • 13.3.7. Simulations Plus expands drug development capabilities with USD 100 million acquisition of Pro-Pro-ficiency Holdings, Inc.
  • 13.3.8. Cellworks unveils new CLIA-certified lab in Tennessee enhancing personalized NSCLC treatment with biosimulation technology and expert leadership
  • 13.3.9. ZETA Group acquires majority stake in INOSIM to revolutionize simulation and engineering in biopharma industry
  • 13.3.10. Innovative cloud-based biosimulation partnership between Exploristics and Exonate revolutionizes clinical trial design for retinal disease therapies
  • 13.3.11. Certara launches Pirana Modeling Workbench 23.10.1 with advanced machine learning and new VPC GUI
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. Simulations Plus, Inc.
  • 13.4.2. Cadence Design Systems, Inc.
  • 13.4.3. Dassault Systemes SE
  • 13.4.4. Certara, Inc.
  • 13.4.5. Thermo Fisher Scientific Inc.

Companies Mentioned

• 1. Advanced Chemistry Development, Inc.
• 2. Aitia
• 3. Allucent
• 4. Biomed Simulation, Inc.
• 5. BioSimulation Consulting Inc.
• 6. Cadence Design Systems, Inc.
• 7. Cell Works Group, Inc.
• 8. Certara, Inc.
• 9. Chemical Computing Group ULC
• 10. Crystal Pharmatech Co., Ltd.
• 11. Cytel Inc.
• 12. Dassault Systemes SE
• 13. ICON PLC
• 14. In Silico Biosciences, Inc.
• 15. INOSIM Software GmbH
• 16. Instem PLC
• 17. Model Vitals
• 18. Physiomics PLC
• 19. Quotient Sciences Limited
• 20. Resolution Medical
• 21. Schrodinger, Inc.
• 22. Simulations Plus, Inc.
• 23. Thermo Fisher Scientific Inc.
• 24. VeriSIM Life
• 25. VIRTUALMAN
• 26. Yokogawa Electric Corporation